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Medicine and Transplant Surgery, University of California San Francisco, San Francisco, United StatesSummary speciﬁcally decompensated cirrhosis and hepatocellular carci-Since the early 1990’s, hepatitis B immune globulin (HBIG) has
been central to the prevention of hepatitis B virus (HBV) recur-
rence after liver transplantation. When used in combination with
oral nucleos(t)ide analogues, HBIG prevents reinfection with HBV
in P90% of transplant recipients. While HBIG is highly efﬁca-
cious, its use is undermined by its high cost. Because of this lim-
itation, there have been many studies of alternative regimens
seeking to minimize the dose or duration of HBIG without sacri-
ﬁcing low HBV recurrence rates. Toward that goal, lower dose
intramuscular HBIG in combination with oral nucleos(t)ide
analogues has been shown to be highly efﬁcacious in preventing
disease recurrence and represents a signiﬁcant cost savings when
compared with high dose intravenous administration. The with-
drawal of HBIG after a deﬁned course of combination HBIG and
oral antivirals has also been shown to be effective, particularly
if combination antiviral therapy is used. The ability to achieve
undetectable HBV DNA levels pre-transplantation in the majority
of patients may contribute to the high efﬁcacy of these HBIG
‘‘light’’ regimens. Additionally, the success of antiviral rescue
therapy for those patients who fail prophylaxis and develop
recurrent HBV infection post-transplant has provided the impe-
tus to move increasingly towards HBIG-free approaches. New
techniques to detect occult HBV in hepatic and extrahepatic sites
may allow clinicians to deﬁne a subgroup of patients in whom
withdrawal of HBIG or all prophylaxis may be applicable.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Infection with chronic hepatitis B affects approximately 360
million people worldwide [1] and over 500,000 deaths per year
are due to complications arising from chronic HBV infection,Journal of Hepatology 20
Received 9 June 2011; received in revised form 1 August 2011
⇑ Corresponding author. Address: University of California San Francisco, San
Francisco, 513 Parnassus Ave, S357, Box 0538, San Francisco, CA 94143, United
States. Tel.: +1 (415) 476 2227; fax: +1 (415) 476 0659.
E-mail address: Norah.Terrault@ucsf.edu (N.A. Terrault).
Abbreviations: HBIG, hepatitis B immune globulin; HBV, hepatitis B virus; HBsAg,
hepatitis B surface antigen; HbsAb, hepatitis B surface antibody; HBeAg, hepatitis
B e antigen; PBMCs, peripheral blood mononuclear cells; ccc DNA, covalently
closed circular DNA; HBV DNA, hepatitis B virus DNA; HCC, hepatocellular
carcinoma.noma (HCC). Liver transplantation offers a life saving alternative
for those affected by the sequelae of chronic infection or with ful-
minant hepatitis. Hepatitis B immune globulin (HBIG) has played
a central role in prophylaxis against recurrent hepatitis B in those
undergoing liver transplantation. Prior to its routine use as
immunoprophylaxis, recurrence of HBV in the liver allograft
occurred in up to 80%, and infrequently was associated with an
aggressive ﬁbrosing cholestatic variant that caused progressive
graft dysfunction and signiﬁcant mortality. The subsequent avail-
ability of safe andeffective antiviral drugs led to additional survival
beneﬁtsby improvingprophylactic efﬁcacyandpreventingdisease
progression in thosewith recurrence.Moreover,with the advent of
effective prophylactic therapies, the occurrence of the aggressive
ﬁbrosing cholestatic variant is rarely reported. Thus, in the past
10–15 years, HBV-infected patients have gone from having the
poorest post-transplant outcomes to having survival rates among
the best of all transplant recipients [2]. Currently, the 5-year graft
survival for those transplanted for HBV is 85% and retransplanta-
tion for recurrent HBV cirrhosis is a rarity. Finally, in the past
5 years, twohighly potent antivirals, entecavir, and tenofovir, have
been approved for the treatment of chronic HBV and their use in
the transplant setting and their high efﬁcacy in suppressing HBV
replication long-term with minimal risk of resistance, has led
many transplant physicians to wonder if the time has come for
abandonment of HBIG in favor of antiviral drug therapy alone. In
this review, we consider the historical and current role of HBIG
and argue that formany, if notmost patients,HBIGdiscontinuation
may be considered. However, an HBIG-free regimen cannot be
endorsed for all patients undergoing transplantation.Historical perspective on HBIG as prophylactic therapy
Hepatitis B immune globulin (HBIG) is a polyclonal antibody to
HBV surface antigen (HBsAg) derived from pooled human plasma.
Although its mechanism of action is incompletely understood, it
is thought that HBIG acts in the circulation by preventing hepato-
cyte infection, binding to and neutralizing circulating virions
expressing HBsAg and perhaps inciting lysis of infected cells
[3]. Within the liver, HBIG may prevent cell-to-cell infection as
well as reduce HBsAg and virion secretion upon endocytosis into
hepatocytes [4]. In transplant recipients, HBV reinfection is the
consequence of either immediate reinfection of the graft by circu-
lating HBV particles or by immediate or delayed reinfection of the
graft from virions from extrahepatic sites or both. To be maxi-
mally protective, HBIG is used during the anhepatic phase (when12 vol. 56 j 1189–1197
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total body viral burden is at its lowest) and given frequently (typ-
ically daily) for the week following transplantation to provide
maximal protection against reinfection of the liver graft during
the time of highest levels of immunosuppression.
The pivotal multicenter European trial published by Samuel
and colleagues nearly 20 years ago demonstrated that long term
administration of intravenous (IV) HBIG reduced hepatitis B
recurrence rates from 75% to 36% and was associated with
improved graft and patient survival [5]. Subsequent trials, using
variable schedules for HBIG administration, conﬁrmed the efﬁ-
cacy of HBIG as a monotherapy against recurrent HBV but also
brought to light the potential for emergence of surface gene
mutations post-transplant conferring resistance to HBIG and
resulting in graft reinfection [6–8]. The HBV surface mutations
associated with HBIG use also resulted in changes to the poly-
merase, and, in one case report, led to reduced viral sensitivity
to antiviral agents [9].
The negative effects of pretransplant viremia could be largely
overcome by use of high doses of HBIG, but such prophylaxis
came at high cost [10]. High dose HBIG given intravenously daily
for the ﬁrst week and monthly thereafter typically cost $50,000–
70,000 for the ﬁrst year and $25–40,000 for each additional year
post-transplant [10]. While this cost represents a major burden in
developed countries, it represents even more of a problem in less
developed HBV-endemic nations. With cost as such a signiﬁcant
barrier, substantial efforts have been made to devise strategies
that minimize HBIG use while maintaining low rates of viral
recurrence.The role of antiviral drugs in management of transplant
recipients
Inhibition of viral replication is an alternative mechanism to
protect grafts from HBV recurrence after transplant (Table 1).Table 1. Trials using antiviral monotherapy as prophylaxis. (See below-mentioned r
Author,
yr,
location
[Ref.]
Drug 
under study
Study population and 
protocol
Pre-treatment 
Perillo et al., 
2001
USA and 
Canada
[11]
Lamivudine n = 37 
Lamivudine (100 mg daily) 
pre and post-transplant
No HBIG
At transplant:
6/37 (16%)  HB
Pre-lamivudine
(54%) HBV DN
Lo et al., 
2001
Hong Kong
[60]
Lamivudine n = 31 
Lamivudine 100 mg daily 
pre and post-transplant
No HBIG
At transplant:
6/31 (19.3%) H
Pre-lamivudine
(35.4%) HBV D
Schiff et al., 
2007
USA, Hong 
Kong, 
Germany, 
Greece, 
Italy, 
France, 
Canada
[12]
Adefovir n = 23 with 
Lamivudine-resistant HBV
Adefovir 10 mg daily 
pre and post-transplant 
No HBIG
Mean serum HB
pre-transplant: 
log10 copies/ml
virologic profile
1190 Journal of Hepatology 2012A multicenter trial conducted at ten centers in the United States
and Canada evaluated the use of lamivudine as a monotherapy in
the pre- and post-liver transplant setting and found that after at
least 12 weeks of post-transplant lamivudine therapy, 60%
remained HBsAg negative, a rate comparable to that seen with
long term HBIG monotherapy [11]. The majority of those with
recurrence had HBV polymerase mutations (12 of 17) and base-
line (pre-lamivudine) HBV DNA levels were higher in those
who developed post-transplant recurrence compared to those
who did not – 82% in those with HBV DNA levels greater than
500,000 IU/ml and 11% in those <50,000 IU/ml – and the med-
ian duration of lamivudine treatment pre-transplant was only
80 days. In a prospective cohort study of 61 patients with lamivu-
dine-resistance chronic HBV infection who were waitlisted and
transplanted, 40% received only adefovir (with and without lam-
ivudine) therapy post-transplant and none developed recurrent
HBV infection (deﬁned by persistently detectable HBsAg or HBV
DNA) at a median follow-up of 36 weeks. HBV DNA levels at time
of transplant were unknown but the median duration of therapy
pre-transplant was 15 weeks [12]. Finally, a non-randomized
study of 60 patients treated with lamivudine pre-transplant
and with undetectable (by PCR) HBV DNA at time of transplanta-
tion showed no signiﬁcant difference in recurrence rates in those
treated with lamivudine monotherapy (15%) compared to those
treated with lamivudine plus HBIG (18%) after median 60-month
follow-up [13].
These studies highlight the feasibility of using antiviral mono-
therapy as prophylaxis but also point to the potential limitations.
Firstly, as shown by the lamivudine monotherapy experience, the
emergence of drug resistance pre- or post-transplantation limits
the efﬁcacy of treatment. Secondly, HBV DNA levels prior to
transplant (inﬂuenced by pre-treatment HBV DNA levels and
duration of pre-transplant therapy) inﬂuence risk of recurrence.
These two issues are strongly inﬂuenced by the choice of antiviral
drugs.efernces for further information.)
Median 
follow-up time
(range)
Outcomes Resistance 
detection
V DNA+ 
 therapy: 20/37 
A+  
38 mo 
(2.7-48.5)
Virologic response: 
after 52, 104 and 
156 wk, 68%, 69% 
and 59% HBsAg-
15/47 
(32%)  
BV DNA+
 therapy: 11/31 
NA+
16 mo 
(6-47)
Virologic response: 
7/31 (22.5%) 
HBsAg+
6/7 HBsAg+ but 
undetectable HBV 
DNA
1/31 (3.2%) 
at 53 wk
V DNA levels 
4.78 (± 1.67) 
36 wk Virologic response:
2/23 (9%) HBsAg+
3/23 (13%) had 
HBV DNA >1000 
copies/ml 
(2/3 became 
undetectable on 
follow-up)
No viral 
resistance 
was 
observed at 
48 wk
vol. 56 j 1189–1197
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With the availability of more potent antivirals with a higher
genetic barrier to resistance (i.e. entecavir, tenofovir), the ability
to successfully suppress HBV in both the pre- and post- transplant
setting has increased, although data on the use of these drugs in
wait-listed and transplanted patients are limited. Liaw and col-
leagues recently demonstrated that tenofovir, emtricitabine/ten-
ofovir, and entecavir could be used safely in patients with
decompensated liver disease and 70.5%, 87.8%, and 72.7% of
patients, respectively, achieved HBV DNA <400 copies/ml by
48 weeks of treatment [14]. Thus, entecavir and tenofovir offer
the beneﬁts of safety and efﬁcacy in the treatment of decompen-
sated liver disease, allowingmorepatients to have anundetectable
HBV DNA level pre-transplantation, in turn, decreasing their risk
for recurrent disease post-transplant. Importantly, these drugs
also have a role as salvage therapies in those transplant recipients
who develop recurrence as a consequence of resistance [15].
It must be acknowledged that safety data on the long-term
use of entecavir, tenofovir, and emtricitabine/tenofovir in trans-
plant recipients are lacking. Special consideration must be given
to potential side effects in these populations. The dose dependent
nephrotoxicity associated with tenofovir may be enhanced in
transplant patients on calcineurin inhibitor therapy. To date,
the limited reports have not revealed a substantially increased
risk of renal dysfunction [14–16]. In studies evaluating the
long-term safety of tenofovir in HIV-infected patients, there
appears to be a risk of decreased bone density and development
of osteomalacia [17]. It is increasingly recognized that metabolic
bone disease represents a signiﬁcant problem in transplant recip-
ients, thus long-term tenofovir use should warrant monitoring of
bone health [18]. Mitochondrial toxicity appears to be a class
effect of the nucleoside analogues, and entecavir has been associ-
ated with the potentially fatal side effect of severe lactic acidosis
in those with advanced decompensated cirrhosis and clinicians
need to be aware of the potential for this complication with use
of any nucleos(t)ide analogue [19].Prophylactic therapy with combination HBIG and antivirals
The use of antibody therapy together with antivirals provides
complementary mechanisms of HBV prevention and a reduced
likelihood of recurrent infection due to the emergence of drug-
resistance viral variants. Markowitz and colleagues ﬁrst
described the efﬁcacy of HBIG combined with lamivudine in
1998 [20]. Of 14 patients who received high dose (10,000 IU)
intravenous HBIG intraoperatively and postoperatively in combi-
nation with lamivudine pre- and post-transplant, all patients
remained without virologic or serologic evidence of HBV recur-
rence after a median of 1.1 years follow-up. Many other reports
of high efﬁcacy with combination therapy followed, with 610%
incidence of recurrent HBV, and establishing combination HBIG
and antivirals as the standard of care for prophylaxis [21–23].
However, the cost of prophylaxis with HBIG was signiﬁcant and
strategies that minimized HBIG use while maintaining low rates
of viral recurrence evolved. Use of lower doses of HBIG, shorter
duration of HBIG or alternative and cheaper forms of antibody
therapy (hepatitis B immune plasma and active immunization)
have been examined as alternatives.
Most of the published literature describing the use of combi-
nation HBIG and antivirals utilizes lamivudine and/or adefovir as
the antivirals. However, even better results may be predictedJournal of Hepatology 2012combining HBIG and a more potent antiviral agent such as ente-
cavir or tenofovir. In a retrospective cohort study by Xi et al., none
of the 30 patients treated with low dose intramuscular HBIG and
entecavir post-transplant had recurrence as opposed to 10 out of
90 (11%) who received lamivudine with low dose HBIG [24].
Notably, over half of those treated with entecavir had detectable
HBV DNA in the serum and 9 out of 30 were HBeAg positive pre-
transplant. Thus, prophylactic therapy using HBIG and an antivi-
ral with a high genetic barrier to resistance is highly effective.Alternative HBIG dosing strategies
In general, there are two principle strategies that have been used
to reduce HBIG doses: (i) low dose (400 IU typically) intramuscu-
lar (IM) HBIG on a ﬁxed weekly to monthly schedule; and (ii)
HBIG given ‘‘on-demand’’ guided by maintenance of serum
anti-HBs titers greater than 50–100 IU/L. Both approaches are
less costly than high and ﬁxed dose HBIG. Gane and colleagues
demonstrated that low dose IM HBIG (400–800 IU daily for a
week and monthly thereafter) used in combination with lamivu-
dine (started pre-transplant) was efﬁcacious (HBV recurrence 1%
at one year and 4% at ﬁve years) and was less than 10% of the cost
of high dose intravenous HBIG regimens [23]. Notably, a high
level of HBV viremia (>106 copies/ml) prior to lamivudine initia-
tion was the most signiﬁcant predictor of post-transplant HBV
recurrence in their cohort. Zheng and colleagues treated 114
patients with low dose IM HBIG (800 IU daily for 6 days, weekly
for 3 weeks, then monthly thereafter) in combination with lami-
vudine, and observed an overall rate of HBV recurrence of 15.2%
at 2 years but with a signiﬁcantly higher rate of prophylaxis fail-
ure in those with HBV DNA levelsP105 copies/ml at transplanta-
tion compared to those with HBV DNA levels <105 copies/ml (28%
vs. 8% p = 0.015) [25]. Thus, a key component to the success of
this low-dose HBIG approach is the virologic proﬁle of the patient
prior to transplantation with risk of recurrence primarily affected
by the presence of high HBV DNA titers.
One advantage of using HBIG therapy is the ability to monitor
the protective capacity of the treatment bymeasurement of serum
anti-HBs levels. Initial studies of HBIG monotherapy established
that higher protective titers were needed in the immediate and
early post-transplant period compared with later (>3 months)
post-transplant [26]. While an ‘‘on-demand’’ approach to HBIG
dosing to achieve a speciﬁc anti-HBs target in the serum may be
more cost-effective, this approach requires more intensive moni-
toring of anti-HBs titers as the amount of HBIG needed tomaintain
a target anti-HBs titer is highly variable between patients. Addi-
tionally, the optimal anti-HBs titer needed to prevent recurrence,
if potent antiviral therapy is given concurrently, is unknown. In
the HBIG monotherapy era, a titer of P500 U/L was shown to be
best in theﬁrst 3 months post-transplant andP100 U/L thereafter.
In the current era of combination HBIG and antivirals, a target
trough anti-HBs titer of 50–100 U/L is typically used. Iacob et al.
reported on 42 subjects initially given high dose IV HBIG
(10,000 IU weekly) then 2500 IU when anti-HBs titers fell below
50 IU/L [27]. With this strategy, only 4.8% of subjects experienced
HBV recurrence after a median of 1.8 years of follow-up. In studies
using intramuscular HBIG, given ‘‘on demand’’ to maintain trough
anti-HBs titers of at least 50–100 IU/L, in conjunctionwith lamivu-
dine the rates of virologic recurrence were 68.2% with follow-up
periods of 3–93 months [28–30]. Factors associated withvol. 56 j 1189–1197 1191
Table 2. Trials of HBIG discontinuation with long-term antiviral therapy. (See below-mentioned refernces for further information.)
Authors, 
yr
[Ref.]
Location Study protocol % HBV DNA- 
at time of transplant 
n Follow-
up 
duration
HBsAg+ 
n (%)
Factors linked 
with recurrence
Park et al., 
2002 [61]
Single 
center, North 
Korea
Randomized to either long term high 
dose HBIG n = 20 or one week high 
dose HBIG + LMV maintenance 
(n = 23)
14% (HBV DNA- 43 Median 
17 mo
1/20 (5%) in HBIG
3/23 (13%) in LMV 
maintenance
1 of 3 patients in LMV maintenance group did 
not receive proper LMV dosing suggesting that 
resistance may be a factor
Buti et al., 
2003 
[42]
7 centers, 
Spain
Randomized trial 
All patients received HBIG and LMV 
for 1 month then randomized to 
HBIG + LMV continuation (n = 15) or 
solo LMV (n = 14) 
100% (HBV DNA- 29 Mean 
83 mo
1/15 (6.7%) in the 
HBIG + LMV group
3/14 (21.4%) in the 
LMV group
HBV recurrence at 23, 24, 44 and 48 mo
3 of 4 cases were associated with poor compli-
ance to LMV; 1 associated with poor compliance 
to HBIG
Wong et al., 
2007 
[44]
Single 
center, 
USA
Retrospective cohort of patients 
given at least 7 doses of HBIG and 
discontinued it but were maintained 
on nucleos(tide) analogue therapy
as: <1.5 log copies/ml)
21 Median 
40.2 mo
1/21 (4.7%) n = 1 with recurrence received LMV for only 3 
mo prior to LT although did achieve viral 
negativity at the time of LT
The patient was lost to follow-up in the post-op 
period for period post-LT – possibly related to 
compliance?
Neff et al., 
2007
[46]
U Cincinnati, 
USA
Retrospective cohort
HBIG + LMV x 6 mo 
adefovir + LMV
100% (HBV DNA- 10 Mean 
31 mo
0 n.a.
Angus et al., 
2008
[47]
Australia, 
New Zealand
Randomized trial
All patients were ≥12 mo post-LT 
low dose IM HBIG + LMV 
(n = 18) continued HBIG with LMV 
vs. (n = 16) discontinued HBIG and 
ADV added (LMV + ADV)
77% (HBV DNA- 
ml)
34 Median 
21 mo
0/18 in HBIG + LMV 
1/16 (6.3%) in LMV 
+ ADV
One patient with  HBsAg+ 5 mo after withdrawal 
of HBIG and remained HBV DNA- by PCR (lower 
limit of detection 14 IU/ml) 
There was no clinical or biochemical hepatitis 
apparent
Yuefeng et 
al., 
2010
[45]
China Retrospective cohort
All patients received HBIG for <18 
mo and used LMV as maintenance
as: <1000 copies/ml)
15 Mean 
56 mo
2/15 (13%) Both patients had high pre-LT HBV DNA titers 
(8.5 and 7.6 log copies/ml) and were HBeAg+ 
pre-LT
the time of recurrence
Saab et al., 
2011
[48] 
UCLA, 
USA
Retrospective cohort
IM HBIG + LMV (at least 12 mo) 
LMV or entecavir + ADV or 
tenofovir
78.6% (HBV DNA- 61 Mean 
15 mo
2/61 (3.3%) Both cases developed HBsAg+  at 3.1 and 16.6 
mo after HBIG withdrawal without detectable 
HBV DNA or elevation in liver enzymes 
Both had undetectable HBV DNA prior to LT
Lenci et al., 
2011 
[58]
Italy Retrospective cohort 
HBIG and oral antivirals 
(LMV ± ADV) were withdrawn after 
serial biopsy specimens negative for 
total and ccc HBV DNA
100% (HBV DNA-
5 copies/ml 
(1993-2000); <400 copies/
ml (2000-2005)
30 Median 
28.7 mo
5/30 (17%) All 5 cases of recurrence were HBV DNA and 
HBeAg- at the time of LT; 2/5 did not have 
pre-LT antiviral therapy
2 had HDV coinfection, 1 had HCV coinfection
Teperman 
et al., 
2011
[41]
6 centers, 
USA
Randomized trial 
24 wk of HBIG + tenofovir/
emtricitabine (TVD) then 
randomized to either continue HBIG 
+ TVD or discontinue HBIG and 
continue TVD
100%  (HBV DNA-) 37 96 wk 0 None HBsAg+; 1 had transiently low level HBV 
DNA associated with medication noncompliance 
defined as: n.a.)
No other factors identified
defined as: <2.5 pg/ml)
29% (HBV DNA- defined
defined as: <50 copies/ml)
defined as: <300 copies/
73% (HBV DNA- defined
Both had LMV resistance mutations identified at
defined: n.a.)
defined as: <10
n.a., not available.
Frontiers in Liver Transplantationrecurrence were higher pre-transplant HBV DNA levels, presence
of lamivudine-resistant HBV, and post-transplant antibody titer.
Jiang and colleagues used low-dose HBIG combined with lamivu-
dine in 254 patients with a target anti-HBs level of P100 IU/ml.
The level of anti-HBs was monitored weekly for the ﬁrst month,
and if the level of anti-HBs was >100 IU/L at the end of the ﬁrst
month, 800 IU per month was subsequently given and if not,
800 IU HBIG was given every 2 weeks [30]. If the serum anti-HBs
level still fell below 100 IU/L, the dose was increased to 1200 IU
every 2 weeks. With this approach, rates of recurrent HBV at 1, 3,
and5 years post-transplantwere 2.3%, 6.2%, and8.2%, respectively.
Pre-transplant HBV DNA levels P105 copies/ml (HR = 5.1,
p = 0.003) and withdrawal of prednisone beyond 3 months
(HR = 2.3, p = 0.003) were the only factors predictive of HBV
recurrence.
In summary, these studies have established that high-dose
intravenous HBIG is neither necessary nor cost-effective as a
long-term prophylactic strategy when combined with antivirals,
and that low-dose, intramuscular HBIG regimens can be used.
Whether higher doses of HBIG offer speciﬁc beneﬁts in the very
early post-transplant period is unclear from the available litera-
ture. Many centers use more HBIG in the anhepatic phase and
ﬁrst week post-transplant, than beyond the ﬁrst week [22]. Addi-
tionally, these studies highlight the importance of pre-transplant
HBV DNA levels as a predictor of prophylaxis failure. This latter1192 Journal of Hepatology 2012association can be used to make recommendations for a more
individualized approach to prophylaxis.
HBIG replacement with vaccination
Active immunization using HBV vaccines post-transplantation is
an attractive alternative to frequent HBIG injections or infusions.
This strategy has yielded conﬂicting results and therefore
remains controversial. Sanchez-Fueyo and colleagues reported
on the success of active immunization in 14 out of 17 (82%) cases
who were treated with HBIG monotherapy followed by one or
two courses of double dose vaccination series [31]. Similarly,
Bienzle et al. demonstrated that 16/20 patients on HBIG prophy-
laxis responded to a series of vaccination [32]. Later, Angelico
et al. showed that this strategy was ineffective with success rates
of up to only 18% in those who discontinued HBIG and remained
on lamivudine [33]. Several other trials have also demonstrated
poor outcomes with various vaccination strategies, with either
lack of initial response or failure to maintain protective anti-
HBs levels over time [34–37]. Newer data have emerged that
suggest administration of either booster doses, double dose
third generation recombinant vaccines or the addition of adju-
vants given with the vaccine may enhance the vaccination
response and decrease formation of escape mutants, however,
additional larger scale studies are needed prior to this strategyvol. 56 j 1189–1197
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being recommended as an alternative to passive immunoprophy-
laxis [38–40].
HBIG discontinuation after prior combination therapy
Strategies aimed at HBIG discontinuation after a deﬁned period of
combination therapy of HBIG and nucleos(t)ide analogues reduce
the costs and inconvenience associated with providing HBIG
long-term. As highlighted in Table 2, most of the published stud-
ies are single center observational studies but three randomized
controlled studies have been performed [41,42,47].
Buti and colleagues randomized 29 patients (all of who were
HBV DNA negative and 25 anti-HBe positive) prior to transplant
to receive lamivudine in combination with intramuscular HBIG
or to discontinue HBIG after one month and continue lamivudine
therapy alone [43]. While none developed recurrent HBV on the
basis of HBsAg positivity in serum after 18-month follow-up, 1/
14 in the lamivudine group and 3/15 in the HBIG/lamivudine
group developed HBV DNA positivity. In a subsequent longer-
term follow-up of this cohort in with six subjects in the combina-
tion group crossed over to the lamivudine monotherapy group
after 18 months of combination therapy, 3/20 patients receiving
lamivudine monotherapy developed HBsAg positivity, all occur-
ring between 23 and 48 months post-transplant and all in associ-
ation with poor lamivudine compliance [42].
More recently, the use of emtricitabine/tenofovir after HBIG
discontinuation was evaluated by Teperman et al. [41]. In this
randomized trial, subjects at a median of 3.4 years after trans-
plant with no evidence of recurrent HBV and creatinine clearance
P40 ml/min were treated with combination emtricitabine/ten-
ofovir and HBIG for 24 weeks and then randomized to continue
that regimen (N = 19) or discontinue HBIG and continue emtricit-
abine/tenofovir alone (N = 18). 47% of all patients had detectable
HBV DNA at the time of transplant. At 72 weeks post-randomiza-
tion, only one patient in the emtricitabine/tenofovir group devel-
oped a transient increase in HBV DNA to 314 copies/ml in the
setting of poor adherence, and ultimately returned to undetect-
able levels on follow-up testing. Although >80% of participants
had baseline mild to moderate renal insufﬁciency at the outset,
no signiﬁcant change in renal function occurred during tenofo-
vir/emtricitabine treatment.
The studies to date highlight several key points related to the
HBIG discontinuation strategy. First, while initial results – ﬁrst
one to two years after HBIG discontinuation – may be favorable,
risk of recurrence may increase over time either due to the devel-
opment of viral resistance or due to non-adherence to the oral
therapy [42,44,45]. Combining antivirals without cross-resistance
reduces the risk of emergence of resistance mutations [46–48]
and would appear to be critical to the success of ‘‘antiviral only’’
maintenance. Whether antivirals such as entecavir or tenofovir,
which have a high genetic barrier to resistance, may be equally
efﬁcacious as single prophylactic agents is unknown and compar-
ative studies of single vs. combination antivirals are needed to
address this issue [41]. Second, as shown with the low-dose HBIG
plus antiviral strategy, the patients with high levels of HBV DNA
at start of treatment or time of transplantation appear to be a
higher risk group for recurrence when HBIG is discontinued and
antivirals alone continued as prophylaxis. The consistency of
pre-transplant HBV DNA levels as a predictor of prophylaxis fail-
ure across the different HBIG minimization studies argues for a
more conservative approach to HBIG withdrawal among wait-
listed patients who are viremic at the time of transplantation.Journal of Hepatology 2012Third, these studies highlight the evolving deﬁnition of recur-
rence, in part related to the greater sensitivity of the HBV DNA
assays. Thus, detection of transient low-level viremia has been
shown in patients on prophylactic therapy without any other
(serologic or clinical) evidence of recurrence. Only patients who
develop HBsAg in serum and persistently detectable HBV DNA
levels are shown to be at risk for clinical disease and graft loss.
Key Points
• The combination of long-term lamivudine and low-dose
HBIG “on demand” or at  intervals can effectively
prevent HBV recurrence rates in ≥90% of transplant
recipients
• HBV prophylaxis should be individualized. Factors of
importance in tailoring the strategy used include
pre-transplant HBV DNA levels, presence of drug-
resistant variants, coinfection with HDV or HIV, and risk
of HCC recurrence
• Discontinuation of HBIG, with continued long-term
nucleos/tide analogue(s) treatment, is another strategy
for prophylaxis that minimizes HBIG use but is most
 in patients with low HBV DNA levels
pre-transplantation
• HBIG-free prophylaxis is best suited for compliant
patients who have a low baseline risk for HBV
recurrence
• Effective antiviral therapies exist to “rescue” patients who
fail initial prophylaxis, thereby limiting graft losses due to
recurrent HBV disease
• HBV persists in the liver or extrahepatic sites and serves
as a source for reactivation, supporting the use of long-
term,  prophylactic therapy in most patients
fixed
efficacious
indefinite
HBIG-free prophylaxisThe high efﬁcacy of prophylaxis using shorter-term HBIG with
long-term antiviral therapy begs consideration of the next step
– the complete elimination of HBIG in prophylactic regimens.
Such a strategy is possible only in the setting of potent antivirals
that have a high genetic barrier to resistance such as entecavir
and tenofovir. Published experience with an HBIG-free prophy-
lactic approach is limited. Wadhawan and colleagues reported
preliminary data on 56 patients who received various antivirals
pre-transplant (combination lamivudine and adefovir in 17, ent-
ecavir in 25, tenofovir in 8 and combination entecavir and tenofo-
vir in 2) [49]. Of the 56 subjects, 47 achieved a HBV DNA level of
<2000 IU/ml prior to transplant and did not receive HBIG at or
post-transplantation. After a median follow-up of 20 months, all
were HBV DNA negative. More recently, Fung and colleagues
have published data on 80 patients undergoing transplant for
complications of chronic HBV infection who were maintained
on an ‘‘HBIG free’’ regimen consisting of entecavir monotherapy
[50]. In this cohort, 33 (41%) were not on antiviral therapy prior
to starting entecavir and only 21 (26%) had undetectable HBV
DNA at the time of transplant. Using entecavir monotherapy after
transplant, the cumulative rate of HBsAg clearance approached
90% at one year. Interestingly, a key determinate of HBsAg lossvol. 56 j 1189–1197 1193
Table 3. Trials demonstrating detection of HBV DNA in intra and extrahepatic sites. (See below-mentioned refernces for further information.)
Author, 
yr
[Ref.]
Prophylactic 
regimen
Pre-LT 
virologic data
Follow-up
duration (mo)
(range, mo)
Post-LT 
virologic data
Roche et al., 
2003
[62]
44 HBsAg+ patients treated with high 
dose post-operative IV HBIG, then HBIG 
for anti-HBs levels >100 U/L 
HBsAg+:
44/44 (100%)
Serum HBV DNA+:
0/44 (0%)
Mean 82 
(0-159)
HBsAg+: 
6/44 (14%)
Serum HBV DNA+: 
18/44 (41%) 
PBMC HBV DNA+:
13/44 (30%) 
Total intrahepatic HBV DNA+:
10/44 (23%)
Intrahepatic cccDNA+:
1/44 (2.3%)
Hussain et al., 
2007
[59]
23/25 (92%) received HBIG + LMV
1/25 (4%) received solo HBIG
1/25 (4%) received HBIG + LMV + ADV
Serum HBV DNA+:
12/25 (48%)
HBeAg+ ;
20/25 (80%)
Median 30
(6-57)
Intrahepatic total and cccDNA+:
7/25 (28%)
Total intrahepatic DNA+ and cccDNA-:
14/25 (56%)
Total and cccDNA-: 
4/25 (16%)
Cheung et al., 
2010
[63]
28/31 received LMV
2/31 received LMV + ADV
Serum HBV DNA+:
23/31 (74%)
Median 44.5
(13.6-126.4)
HBsAg+:
0/31 (0%)
Serum HBV DNA+:
0/31 (0%)
PBMC HBV DNA+:
0/31 (0%)
Total intrahepatic HBV DNA+:
26/31 (84%)
Intrahepatic cccDNA+:
16/31 (52%)
Lenci et al., 
2010
[64]
44/44 (100%) received HBIG
15/44 (34%) also received LMV or ADV
HBsAg+:
44/44 (100%)
HBeAg+: 
2/44 (4.5%)
HBV DNA-:
44/44 (100%)
Mean 88.3
(18-159)
HBsAg+:
1/44 (2.3%)
Serum HBV DNA+:
1/44 (2.3%)
Total intrahepatic HBV DNA+:
3/44 (6.8%)
Intrahepatic cccDNA+:
1/44 (2.3%)
et al., 
2011
[65]
12/12 (100%) received long term HBIG  
and antiviral therapy 
(LMV ± ADV; ADV; entecavir; tenofovir)
Serum HBV DNA+:
in 7/12 (58%)
Median 18
(12-180)
HBsAg+: 
2/12 (17%)
Serum HBV DNA+:
11/12
Coffin
Frontiers in Liver Transplantationwas the pre-transplant quantitative HBsAg level – such that those
with lower HBsAg titers (<3log IU/ml) had a signiﬁcantly higher
rate of HBsAg seroconversion at one year (90% vs. 74%,
p = 0.025). In those with persistent or recurrent HBsAg, the pre-
transplant median HBsAg titers were also shown to be signiﬁ-
cantly higher than in those without persistence/recurrence. Inter-
estingly, low pre-transplant HBV DNA levels alone were not
signiﬁcantly associated with HBsAg loss, however, when a low
HBV DNA (<5log copies/ml) was paired with a low HBsAg level
(<3log IU/ml) the cumulative rate of HBsAg seroconversion at
18 months was 100%.
While the Wadhawan study emphasizes the importance of
achieving pre-transplant HBV DNA negativity in patients being
treated with antiviral alone as prophylaxis [49], the study by
Fung and colleagues highlights the role of both pre-transplant
HBV DNA levels and quantitative HBsAg levels [50]. Additional
studies examining the utility of HBsAg levels in predicting
post-transplant outcomes in patients on antiviral prophylaxis
warrant consideration.
The key questions going forward include: (i) whether single
drug or combination antiviral therapy is best; (ii) whether all1194 Journal of Hepatology 2012patients can be managed without HBIG or whether there are sub-
groups of patients with a high risk of recurrence with antivirals
alone that should receive combination HBIG and antivirals; and
(iii) what antiviral strategy is most cost-effective?
Monotherapy or combination antiviral therapy?
A potential risk with using a single oral antiviral drug for prophy-
laxis is the emergence of viral resistance. Use of drugs with a high
genetic barrier to resistance such as entecavir and tenofovir are
superior to drugs such as lamivudine and adefovir, as shown in
non-transplant patients [51,52]. The combination of a nucleotide
analogue with an nucleoside analogue has been associated with a
very low rate of virologic breakthrough and the speciﬁc combina-
tion of lamivudine and adefovir has shown efﬁcacy in the
transplant setting [12,53]. Thus, the combination of a nucleoside
and nucleotide analogue may represent the most effective long-
term prophylactic strategy (Table 3). However, in the aforemen-
tioned study by Fung and colleagues that examined the role of
entecavir monotherapy after transplant, no resistance mutations
were identiﬁed after a median follow-up of 26 months [50]. Thevol. 56 j 1189–1197
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disadvantages of combination antiviral therapy include higher
pill burden (and possibly reduced adherence) and higher cost.
The latter issue would depend upon the individual costs of the
drugs and this varies considerably by country.
Patient and viral factors favoring HBIG-free prophylaxis
The option of HBIG free prophylaxis is easiest to consider in
patients at low risk for recurrence. A consistent theme through-
out the published literature is that HBV DNA levels and presence
of drug-resistance HBV (especially if unrecognized) pre-trans-
plantation are predictive of HBV recurrence post-transplantation.
In the multicenter NIH HBV-OLT Study Group of 183 HBV trans-
plant recipients, the rate of HBV recurrence at 1 and 5 years was
found to be 3% and 9% despite highly variable regimens of com-
bination HBIG and antivirals [54]. The only factors predictive of
recurrent HBV were a positive HBeAg and high HBV DNA level
at transplant (HR = 11.6 and 7.0, respectively). Similarly, Marzano
et al. showed a strong correlation between HBV DNA levels
>105 copies/ml at transplant and higher risk for HBV recurrence
post-transplant [55].
Since the level of viremia at the time of transplantation is such
an important predictor of risk of recurrence, achievement of
pre-transplant viral suppression should be the goal in every
wait-listed patient. Patients achieving this endpoint of therapy
pre-transplant are the best candidates for a consideration of an
HBIG-free prophylactic strategy. In the current era of safe and
highly effective antiviral drugs, few patients should undergo
transplant with detectable viremia. However, for patients with
HCC or who present with advanced decompensated cirrhosis,
there may be insufﬁcient time to achieve an undetectable HBV
DNA level pre-transplant. Thus, those patients who are viremic
at the time of transplant, those at higher risk for HCC recurrence,
as well as those with limited treatment options if prophylactic
therapy fails, such as those with HDV or HIV coinfection, may
be better served by a more conservative approach that utilizes
long-term, low dose HBIG plus antivirals.
Cost revisited
Disadvantages of HBIG therapy include occasional adverse reac-
tions, increased need for laboratory monitoring, and requirement
for parenteral administration. However, the driving force behind
the desire to discontinue HBIG has remained its huge cost, espe-
cially in resource-limited countries. As clinical studies have
demonstrated that alternative HBIG regimens might result in
similarly efﬁcacious outcomes cost savings has been appreciated.
Han et al. compared the cost-efﬁcacy of high dose IV HBIG with
and without lamivudine, IM HBIG and lamivudine with and with-
out IV HBIG savage therapy and ﬁnally lamivudine monotherapy
[56]. The most cost-effective strategy was combination IM HBIG
with lamivudine, which cost $13,500 annually and saved over
$150,000 annually compared to high dose IV HBIG therapy. The
cost-effectiveness of discontinuing HBIG and add a second antivi-
ral drugs was evaluated by Saab et al. [57]. They compared the
strategy of lamivudine and adefovir (after HBIG discontinuation)
with the strategy of lamivudine and continued intramuscular
HBIG with the addition of adefovir in patients who subsequently
developedhepatitis B recurrence. Patientswho failedwithadefovir
and lamivudine were then treated with tenofovir and entecavir.
Over a 10-year period of follow-up the lamivudine-adefovir strat-
egywas favored, yieldinga cost-saving of $14,427. Since the resultsJournal of Hepatology 2012were sensitive to the costs of the antiviral drugs andHBIG, updated
analyses based upon use of drugs such as entecavir and tenofovir
are needed to determine whether combination antiviral therapy
is still cost-saving compared to low dose HBIG and lamivudine.Indeﬁnite prophylaxis is current standard of care
While there is variability in the speciﬁc drugs used for HBV pro-
phylaxis post-transplantation, there is consensus regarding the
provision of prophylactic therapy life-long. The use of long-term
prophylaxis is supported by the detection of HBV DNA in both
hepatic and extrahepatic sites in patients who are HBsAg negative
on post-transplant HBIG and oral antivirals (Table 3). A recent
study by Lenci and colleagues challenged our current thinking
regarding lifelong prophylaxis. These investigators undertook a
discontinuation of all prophylaxis in a cohort of 30 subjects, all at
low risk of HBV recurrence (HBeAg negative and HBV DNA nega-
tive) at the time of transplant [58]. Subjects were treated with
combination HBIG and lamivudine (±adefovir) for at least 3 years
and had liver biopsies on prophylaxis that were found to be nega-
tive for the presence of intrahepatic HBV total and ccc DNA. In a
stepwise approach, using the absence of intrahepatic total and
ccc DNA as a guide (via repeated liver biopsies), HBIG and then
antiviral therapywaswithdrawn sequentially. During the analysis
time, 83% of the cohort was without serologic recurrence of HBV
infection after a median of 28.7 months of observation. Twenty-
three of the 25 subjects without recurrence never had detectable
DNA in the tissue specimens, whereas all ﬁve patients with recur-
rence had evidence of total HBVDNA in the tissue and only one had
detected ccc DNA. The ﬁndings of this study suggest that sensitive
molecularmethodsmay be useful in identifying patients whomay
be considered forwithdrawal of prophylaxis.Whetherwithdrawal
of all drugs is a goal achievable by a few or the majority of trans-
plant recipients is completely unknown. Conﬁrmation of the Ital-
ian experience is essential, since no other center has reported
such a low rate of intrahepaticHBVDNAand cccDNAamong trans-
plant recipients on prophylaxis, and the generalizability of results
is uncertain [59]. Additionally, as it has been shown with HBIG
withdrawal studies, prolonged periods of follow-up are needed
to ascertain the long-term risk of recurrence. Practically speaking,
the ability to measure HBV DNA and ccc DNA in histologic speci-
mens has limitations. Firstly, this strategy calls for multiple liver
biopsies. Secondly, assays for quantitation of intrahepatic HBV
DNA and ccc DNA are not standardized and may make interpreta-
tion of study decision points challenging. Nonetheless, this
remains an intriguing area of future research.Individualized propylactic therapy in liver transplant
recipients with HBV
Over the past two decades, our experience with preventing recur-
rence of HBV infection post liver transplantation has grown
considerably. The available prophylactic regimens have allowed
both graft and patient survival to match and even supersede out-
comes seen in non HBV settings [2]. HBIG therapy has remained
central to these prophylactic strategies, but its relatively high cost,
poor availability in some countries, and patient and provider
inconvenience have prompted the investigation of HBIG minimi-
zation or withdrawal. There is compelling evidence that in select
populations, speciﬁcally thosewho are virologically low risk, HBIG
can be successfully discontinued. However, although cost has beenvol. 56 j 1189–1197 1195
Viral factors
• HBV DNA level at transplant
• HBsAg level at transplant
• Presence of drug-resistant HBV
• HDV coinfection
• HIV coinfection
Drug factors
• Genetic barrier to resistance
• Antiviral potency
• Single vs. combination therapy
Patient factors
• HCC
• Non adherence
HBIG + antivirals 
vs.
antivirals alone
(HBIG-free)
Fig. 1. Patient, viral, and drug factors inﬂuencing choice of prophylactic
regimen.
Frontiers in Liver Transplantationthe driving force behind the desire to limit or eliminate HBIG, it is
important to realize that the cost of newer antivirals is consider-
able and may not provide much savings over low dose HBIG plus
lamivudine schedules.
As we continue to reﬁne prophylactic regimens while consid-
ering cost and convenience for patients and practitioners alike,
we should not compromise the prevention of disease recurrence.
Patient, viral, and antiviral factors need to be considered (Fig. 1).
A short course of HBIG or HBIG-free therapy in conjunction with
long-term antiviral therapy appears to be a safe and efﬁcacious
approach for most patients in the current era of potent antivirals
with lower risk of resistance. Patients with an undetectable HBV
DNA levels pre-transplant are best suited for this prophylactic
strategy and achievement of HBV DNA negativity and prevention
of drug resistant HBV is now feasible in the majority of wait-
listed patients. However, for those patients with high pre-trans-
plant HBV DNA levels or those with limited antiviral options
should recurrence develop (i.e. HDV or HIV confection, those with
preexisting drug resistant HBV or those with prior antiviral intol-
erance), a more cautions approach to prophylaxis is necessary. In
these latter groups, HBIG-free prophylaxis cannot be recom-
mended pending more deﬁnitive studies.
Conﬂict of interest
N.T. received grant support from Gilead Sciences and Novartis
and served on advisory boards for Gilead Sciences, Biotest and
Cangene.
References
[1] World Health Organization. Available from <www.who.int>.
[2] Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of
liver transplantation for hepatitis B in the United States. Liver Transpl
2004;10:968–974.1196 Journal of Hepatology 2012[3] Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B
virus graft reinfection following liver transplantation: a concise review.
Hepatology 2000;32:1189–1195.
[4] Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, et al.
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the
secretion of hepatitis B virus surface antigen and virions. J Virol
2003;77:8882–8892.
[5] Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver
transplantation in European patients with the hepatitis B surface antigen. N
Engl J Med 1993;329:1842–1847.
[6] Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis
B virus S mutants in liver transplant recipients who were reinfected despite
hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213–222.
[7] Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al.
Incidence and clinical consequences of surface and polymerase gene
mutations in liver transplant recipients on hepatitis B immunoglobulin.
Hepatology 1998;28:555–561.
[8] Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U. Meyer zum
Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis
B surface antigen is selected by high-dose hepatitis B immune globulin after
liver transplantation. Hepatology 1998;27:254–263.
[9] Shields PL, Owsianka A, Carman WF, Boxall E, Hubscher SG, Shaw J, et al.
Selection of hepatitis B surface ‘‘escape’’ mutants during passive immune
prophylaxis following liver transplantation: potential impact of genetic
changes on polymerase protein function. Gut 1999;45:306–309.
[10] Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis
in liver transplant recipients using a ﬁxed dosing schedule of hepatitis B
immunoglobulin. Hepatology 1996;24:1327–1333.
[11] Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter
United States-Canadian trial to assess lamivudine monotherapy before and
after liver transplantation for chronic hepatitis B. Hepatology
2001;33:424–432.
[12] Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.
Adefovir dipivoxil for wait-listed and post-liver transplantation patients
with lamivudine-resistant hepatitis B: ﬁnal long-term results. Liver Transpl
2007;13:349–360.
[13] Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al.
Lamivudine monoprophylaxis for liver transplant recipients with non-
replicating hepatitis B virus infection. Clin Transplant 2007;21:166–171.
[14] Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong
F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and
entecavir in patients with decompensated chronic hepatitis B liver disease.
Hepatology 2011;53:62–72.
[15] Neff GW, Nery J, Lau DT, O’Brien CB, Duncan R, Shire NJ. Tenofovir therapy
for lamivudine resistance following liver transplantation. Ann Pharmacother
2004;38:1999–2004.
[16] Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, et al. Pre-
vention of lamivudine-resistant hepatitis B recurrence after liver transplan-
tation with entecavir plus tenofovir combination therapy and perioperative
hepatitis B immunoglobulin only. Transpl Infect Dis 2010;13:299–302.
[17] Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, et al. The
safety and efﬁcacy of tenofovir DF in combination with lamivudine and
efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients.
HIV Clin Trials 2007;8:164–172.
[18] Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman
RK, et al. Hepatic osteodystrophy is common in patients with noncholestatic
liver disease. Dig Dis Sci 2011;56:3323–3327.
[19] Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al.
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir
in patients with impaired liver function. Hepatology 2009;50:2001–2006.
[20] Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al.
Prophylaxis against hepatitis B recurrence following liver transplantation
using combination lamivudine and hepatitis B immune globulin. Hepatology
1998;28:585–589.
[21] Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination
low-dose hepatitis B immune globulin and lamivudine therapy provides
effective prophylaxis against posttransplantation hepatitis B. Liver Transpl
2000;6:429–433.
[22] Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the
liver transplantation setting: a European and an American perspective. Liver
Transpl 2005;11:716–732.
[23] Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al.
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent
hepatitis B following liver transplantation. Gastroenterology 2007;132:
931–937.vol. 56 j 1189–1197
JOURNAL OF HEPATOLOGY
[24] Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in
preventing hepatitis B recurrence after liver transplantation. J Dig Dis
2009;10:321–327.
[25] Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis
B recurrence after liver transplantation using lamivudine or lamivudine
combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl
2006;12:253–258.
[26] McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS,
Dickson RC, et al. Improved outcome of orthotopic liver transplantation for
chronic hepatitis B cirrhosis with aggressive passive immunization. Trans-
plantation 1996;61:1358–1364.
[27] Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, et al.
Costs and efﬁcacy of ‘‘on demand’’ low-dose immunoprophylaxis in HBV
transplanted patients: experience in the Romanian program of liver
transplantation. J Gastrointestin Liver Dis 2008;17:383–388.
[28] Karademir S, Astarcioglu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A,
et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B
immunoglobulin and lamivudine after liver transplantation. Transplant Proc
2006;38:579–583.
[29] Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, et al. Low-
dose hepatitis B immune globulin and higher-dose lamivudine combination
to prevent hepatitis B virus recurrence after liver transplantation. Antivir
Ther 2004;9:921–927.
[30] Jiang L, Yan L, Li B, Wen T, Zhao J, Cheng N, et al. Prophylaxis against
hepatitis B recurrence posttransplantation using lamivudine and individu-
alized low-dose hepatitis B immunoglobulin. Am J Transplant 2010;10:
1861–1869.
[31] Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al.
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus
vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence
after liver transplantation. Hepatology 2000;31:496–501.
[32] Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, et al.
Immunization with an adjuvant hepatitis B vaccine after liver transplanta-
tion for hepatitis B-related disease. Hepatology 2003;38:811–819.
[33] Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure
of a reinforced triple course of hepatitis B vaccination in patients
transplanted for HBV-related cirrhosis. Hepatology 2002;35:176–181.
[34] Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance
oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig
Dis Sci 2010;55:505–509.
[35] Karasu Z, Ozacar T, Akarca U, Ersoz G, Erensoy S, Gunsar F, et al. HBV
vaccination in liver transplant recipients: not an effective strategy in the
prophylaxis of HBV recurrence. J Viral Hepat 2005;12:212–215.
[36] Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, et al. Failure of
hepatitis B vaccination with conventional HBsAg vaccine in patients with
continuous HBIG prophylaxis after liver transplantation. Liver Transpl
2007;13:367–373.
[37] Starkel P, Stoffel M, Lerut J, Horsmans Y. Response to an experimental HBV
vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected
chronic HBV-infected liver graft recipients. Liver Transpl 2005;11:
1228–1234.
[38] Lo CM, Lau GK, Chan SC, Fan ST, Wong J. Efﬁcacy of a pre-S containing
vaccine in patients receiving lamivudine prophylaxis after liver transplan-
tation for chronic hepatitis B. Am J Transplant 2007;7:434–439.
[39] Gunther M, Neuhaus R, Bauer T, Jilg W, Holtz JA, Bienzle U. Immunization
with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody
decline and booster vaccination with conventional vaccine. Liver Transpl
2006;12:316–319.
[40] Di Paolo D, Lenci I, Cerocchi C, Tariciotti L, Monaco A, Brega A, et al. One-year
vaccination against hepatitis B virus with a MPL-vaccine in liver transplant
patients for HBV-related cirrhosis. Transpl Int 2010;23:1105–1112.
[41] Teperman LSJ, Poordad F, Schiano T, Bzowej N, Martin P, Coombs D, Hirsch K,
Anderson J. Randomized trial of emtricitabine/tenofovir DF plus/minus HBIG
withdrawal in prevention of chronic hepatitis B recurrence post-liver
transplantation: 48 week results. Abstract presented at American Transplant
Congress, Philadelphia, 2011.
[42] Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. Adherence to
Lamivudine after an early withdrawal of hepatitis B immune globulin plays
an important role in the long-term prevention of hepatitis B virus
recurrence. Transplantation 2007;84:650–654.
[43] Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized
study comparing lamivudine monotherapy after a short course of hepatitis B
immune globulin (HBIg) and lamivudine with long-term lamivudine plus
HBIg in the prevention of hepatitis B virus recurrence after liver transplan-
tation. J Hepatol 2003;38:811–817.Journal of Hepatology 2012[44] Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, et al. Low risk of
hepatitis B virus recurrence after withdrawal of long-term hepatitis B
immunoglobulin in patients receiving maintenance nucleos(t)ide analogue
therapy. Liver Transpl 2007;13:374–381.
[45] Yuefeng M, Weili F, Wenxiang T, Ligang X, Guiling L, Hongwei G, et al. Long-
term outcome of patients with lamivudine after early cessation of hepatitis B
immunoglobulin for prevention of recurrent hepatitis B following liver
transplantation. Clin Transplant 2010;25:517–522.
[46] Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, et al.
Combination therapy in liver transplant recipients with hepatitis B virus
without hepatitis B immune globulin. Dig Dis Sci 2007;52:2497–2500.
[47] Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized
study of adefovir dipivoxil in place of HBIG in combination with lamivudine
as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:
1460–1466.
[48] Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, et al. Posttransplan-
tation hepatitis B prophylaxis with combination oral nucleoside and
nucleotide analog therapy. Am J Transplant 2011;11:511–517.
[49] Wadhawan MGS, Vij V, Goyal N, Dargan P, Rastogi M, Vasu F, et al. Living
related liver transplant (LRLT) in HBV DNA negative cirrhosis without
hepatitis B immune globulin (HBIG). Hepatol Int 2011;5:38.
[50] Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir
monotherapy is effective in suppressing hepatitis B virus after liver
transplantation. Gastroenterology 2011;141:1212–1219.
[51] Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N,
et al. Efﬁcacy and safety of entecavir versus adefovir in chronic hepatitis B
patients with hepatic decompensation: a randomized open-label study.
Hepatology 2011;54:91–100.
[52] Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis
B. N Engl J Med 2008;359:2442–2455.
[53] Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low
resistance to adefovir combined with lamivudine: a 3-year study of 145
lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:
1445–1451.
[54] Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown Jr RS, et al.
Impact of virologic breakthrough and HBIG regimen on hepatitis B recur-
rence after liver transplantation. Am J Transplant 2010;10:1823–1833.
[55] Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W,
et al. Viral load at the time of liver transplantation and risk of hepatitis B
virus recurrence. Liver Transpl 2005;11:402–409.
[56] Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from
intravenous to intramuscular hepatitis B immune globulin in combination
with lamivudine is safe and cost-effective in patients receiving long-term
prophylaxis to prevent hepatitis B recurrence after liver transplantation.
Liver Transpl 2003;9:182–187.
[57] Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for
hepatitis B prophylaxis one year after liver transplantation. Liver Transpl
2009;15:413–420.
[58] Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, et al. Safety
of complete and sustained prophylaxis withdrawal in patients liver trans-
planted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol
2011;55:587–593.
[59] Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS. Presence of
intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence
after liver transplantation. Liver Transpl 2007;13:1137–1144.
[60] Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, et al. Liver transplantation
in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann
Surg 2001;233:276–281.
[61] Park SJ, Paik SW, Choi MS, Lee JH, Koh KC, Kim SJ, et al. Is lamivudine with 1-
week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after
liver transplantation? Transplant Proc 2002;34:1252–1254.
[62] Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al.
HBV DNA persistence 10 years after liver transplantation despite successful
anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86–95.
[63] Cheung Ck, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor
and recipient origin after liver transplantation despite nucleoside analogue
prophylaxis. Liver Transpl 2010;16:1314–1323.
[64] Lenci I, Marcuccilli F, Tisone G, Di Paolo D, Tariciotti L, Ciotti M, et al. Total and
covalently closed circular DNA detection in liver tissue of long-term survivors
transplanted for HBV-related cirrhosis. Dig Liver Dis 2010;42: 578–584.
[65] Cofﬁn CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI,
Terrault NA. Hepatitis B Virus (HBV) quasispecies in hepatic and extrahe-
patic viral reservoirs in liver transplant recipients on prophylactic therapy.
Liver Transpl 2011;17:955–962.vol. 56 j 1189–1197 1197
